Bristol-myers Squibb Compnay

John E Skonier

Anthony W Siadak

Alejandro A Aruffo

Jurgen Bajorath

Anthony F Purchio

Michael A Bowen

Michael G Neubauer

Gary C Starling

Dale L Bodian

The invention provides antibodies and other binding agents that bind specifically to SRCR domains of human CD6 (hCD6) and have advantageous properties, including the capacity to substantially inhibit binding of activated leukocyte adhesion molecule (ALCAM) to hCD6. The binding agents of the invention are useful, inter alia, in methods for screening peptides and drugs that also bind to hCD6 and/or modulate ALCAM binding to hCD6, as well as in diagnostic and therapeutic methods for management and treatment of inflammatory and autoimmune diseases.

Monoclonal antibodies to human CD6

A new TGF-.beta. induced gene and protein is described. Treatment of TGF-.beta. growth arrested cells induces the production of a novel gene which encodes a 683 amino acid protein, designated BIG-H3, that contains four homologous repeat regions and which may represent a cell surface recognition molecule. This gene and protein is induced in mammalian cells, and specifically human cells, upon treatment with TGF-.beta., and is shown to inhibit the growth of tumor cells.

TGF-.beta. induced gene

Growing community of inventors

Seattle, WA, United States of America

John E Skonier